GlassScriptPhysician profile
Christine A Moore
NPI 1790148948
$1,487.26
in general payments reported to CMS, 2019-2025
21 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.61 · 2021: $116 · 2022: $12.22 · 2023: $235 · 2024: $636 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Consulting Fee: $150 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.29 |
| Consulting Fee | $150.00 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244.74 | 2020-2024 | Jemperli, Ojjaara |
| Janssen Scientific Affairs, LLC | $150.00 | 2024 | Talvey |
| Abbvie INC. | $147.53 | 2024-2025 | |
| Pfizer INC. | $116.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.82 | 2023-2024 | Enhertu, Calquence, Imfinzi |
| Celgene Corporation | $106.52 | 2024-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $99.73 | 2024-2025 | Keytruda |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Novocure INC. | $89.19 | 2025 | Optune Gio |
| Genzyme Corporation | $62.17 | 2023-2025 | |
| Array Biopharma INC | $39.90 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Daiichi Sankyo INC. | $28.24 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $27.50 | 2025 | |
| Pharmacosmos Therapeutics INC. | $26.98 | 2025 | Monoferric |
| Janssen Biotech, INC. | $24.02 | 2023 | Darzalex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.47 | 2024 | Osteocool Rf Ablation System |
| Gilead Sciences, INC. | $22.08 | 2023 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Astellas Pharma US INC | $17.86 | 2024 | Padcev |
| Exelixis INC. | $16.68 | 2023 | Cabometyx |
| Lilly USA, LLC | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.